GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Liabilities-to-Assets

Serina Therapeutics (Serina Therapeutics) Liabilities-to-Assets : 1.40 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Serina Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $15.17 Mil. Serina Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $10.86 Mil. Therefore, Serina Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 1.40.


Serina Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Serina Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Liabilities-to-Assets Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Liabilities-to-Assets
20.04 45.03

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Liabilities-to-Assets 20.04 - 45.03 4.62 1.40

Competitive Comparison of Serina Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Serina Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Liabilities-to-Assets falls into.



Serina Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Serina Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=38.636/0.858
=45.03

Serina Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=15.165/10.856
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics  (AMEX:SER) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Serina Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics (Serina Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines